Bladder Cancer - Pipeline Review, H2 2019
Bladder Cancer - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2019, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 73, 85, 1, 2, 81, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 4, 1, 13 and 3 molecules, respectively.
Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2019, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 73, 85, 1, 2, 81, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 4, 1, 13 and 3 molecules, respectively.
Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Bladder Cancer - Overview
Bladder Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bladder Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bladder Cancer - Companies Involved in Therapeutics Development
Bladder Cancer - Drug Profiles
4SC-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
9-ING41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bladder Cancer - Dormant Projects
Bladder Cancer - Discontinued Products
Bladder Cancer - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Sesen Bio initiates rolling submission of BLA for Vicinium to FDA
Dec 05, 2019: FerGene announces pivotal phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS Ta/T1) achieving a complete response at three months
Dec 04, 2019: Sesen Bio completes successful CMC Type B pre-BLA Meeting with FDA
Dec 02, 2019: FDA grants priority review to Merck’s supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC)
Nov 27, 2019: Theralase researchers receive recognition for recent scientific publications
Nov 26, 2019: Cancer Research UK: Bladder cancer treatment rejected for routine use on NHS in England
Nov 08, 2019: Neon Therapeutics announces updated data presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 06, 2019: 4D pharma: Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA
Nov 05, 2019: Sesen Bio Announces successful type C meeting with FDA for Vicinium
Oct 23, 2019: EpiVax Oncology announces three abstracts accepted for presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
Oct 21, 2019: Bavarian Nordic reports Phase II bladder cancer trial data
Oct 07, 2019: London Health Sciences Centre launches as newest clinical study site for phase II Non-Muscle Invasive Bladder Cancer clinical study
Oct 01, 2019: Roche’s Tecentriq performs well in untreated bladder cancer
Oct 01, 2019: Theralase files Investigational New Drug application with the FDA
Sep 30, 2019: Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bladder Cancer - Overview
Bladder Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bladder Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bladder Cancer - Companies Involved in Therapeutics Development
Bladder Cancer - Drug Profiles
4SC-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
9-ING41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bladder Cancer - Dormant Projects
Bladder Cancer - Discontinued Products
Bladder Cancer - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Sesen Bio initiates rolling submission of BLA for Vicinium to FDA
Dec 05, 2019: FerGene announces pivotal phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS Ta/T1) achieving a complete response at three months
Dec 04, 2019: Sesen Bio completes successful CMC Type B pre-BLA Meeting with FDA
Dec 02, 2019: FDA grants priority review to Merck’s supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC)
Nov 27, 2019: Theralase researchers receive recognition for recent scientific publications
Nov 26, 2019: Cancer Research UK: Bladder cancer treatment rejected for routine use on NHS in England
Nov 08, 2019: Neon Therapeutics announces updated data presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 06, 2019: 4D pharma: Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA
Nov 05, 2019: Sesen Bio Announces successful type C meeting with FDA for Vicinium
Oct 23, 2019: EpiVax Oncology announces three abstracts accepted for presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
Oct 21, 2019: Bavarian Nordic reports Phase II bladder cancer trial data
Oct 07, 2019: London Health Sciences Centre launches as newest clinical study site for phase II Non-Muscle Invasive Bladder Cancer clinical study
Oct 01, 2019: Roche’s Tecentriq performs well in untreated bladder cancer
Oct 01, 2019: Theralase files Investigational New Drug application with the FDA
Sep 30, 2019: Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Bladder Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Route of Administration, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Bladder Cancer - Pipeline by 4D Pharma Plc, H2 2019
Bladder Cancer - Pipeline by 4SC AG, H2 2019
Bladder Cancer - Pipeline by Aadi Bioscience Inc, H2 2019
Bladder Cancer - Pipeline by AbbVie Inc, H2 2019
Bladder Cancer - Pipeline by Abivax SA, H2 2019
Bladder Cancer - Pipeline by Actuate Therapeutics Inc, H2 2019
Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2019
Bladder Cancer - Pipeline by Advaxis Inc, H2 2019
Bladder Cancer - Pipeline by Agenus Inc, H2 2019
Bladder Cancer - Pipeline by AIM ImmunoTech Inc, H2 2019
Bladder Cancer - Pipeline by Alligator Bioscience AB, H2 2019
Bladder Cancer - Pipeline by Alphamab Oncology, H2 2019
Bladder Cancer - Pipeline by Altor Bioscience LLC, H2 2019
Bladder Cancer - Pipeline by Amrita Therapeutics, H2 2019
Bladder Cancer - Pipeline by Andes Biotechnologies, H2 2019
Bladder Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2019
Bladder Cancer - Dormant Projects, H2 2019
Bladder Cancer - Discontinued Products, H2 2019
Bladder Cancer - Discontinued Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development for Bladder Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Route of Administration, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Bladder Cancer - Pipeline by 4D Pharma Plc, H2 2019
Bladder Cancer - Pipeline by 4SC AG, H2 2019
Bladder Cancer - Pipeline by Aadi Bioscience Inc, H2 2019
Bladder Cancer - Pipeline by AbbVie Inc, H2 2019
Bladder Cancer - Pipeline by Abivax SA, H2 2019
Bladder Cancer - Pipeline by Actuate Therapeutics Inc, H2 2019
Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2019
Bladder Cancer - Pipeline by Advaxis Inc, H2 2019
Bladder Cancer - Pipeline by Agenus Inc, H2 2019
Bladder Cancer - Pipeline by AIM ImmunoTech Inc, H2 2019
Bladder Cancer - Pipeline by Alligator Bioscience AB, H2 2019
Bladder Cancer - Pipeline by Alphamab Oncology, H2 2019
Bladder Cancer - Pipeline by Altor Bioscience LLC, H2 2019
Bladder Cancer - Pipeline by Amrita Therapeutics, H2 2019
Bladder Cancer - Pipeline by Andes Biotechnologies, H2 2019
Bladder Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2019
Bladder Cancer - Dormant Projects, H2 2019
Bladder Cancer - Discontinued Products, H2 2019
Bladder Cancer - Discontinued Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development for Bladder Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Number of Products under Development for Bladder Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
